

PIVAC-16

16th International Conference

Progress in Vaccination Against Cancer

12 – 14 September 2016 • Winchester, UK



Day 1 - Monday 12 September 2016

11.00 – 13.00	REGISTRATION <i>Entrance Lobby</i> Posters may be put up between 11.00 – 13.00
12.00 – 13.00	WELCOME LUNCH <i>Bapsy Hall</i> Trade Exhibition, Posters & Catering
13.00 – 13.15	OPENING SESSION Christian Ottensmeier University of Southampton (UK) SESSION 1: Title to be confirmed Session Chair: to be confirmed
13.15 – 13.35 Q&A: 13.35 – 13.45	Kevin Harrington The Institute of Cancer Research (UK) “Viral therapy - combinations with other targeted agents?”
13.45 – 14.05 Q&A: 14.05 – 14.15	Stephen Schoenberger La Jolla Institute for Allergy and Immunology (USA) “Towards personalized neoantigen vaccines in HNSCC”
14.15 – 14.35 Q&A: 14.35 – 14.45	Martin Glennie University of Southampton (UK) “Immunostimulatory antibodies for cancer treatment”
14.45 – 15.15	COFFEE BREAK <i>Bapsy Hall</i> Trade Exhibition, Posters & Catering SESSION 2: Title to be confirmed Session Chair: to be confirmed
15.15 – 15.25 Q&A: 15.25 – 15.30	Proffered Paper 1: Author to be selected “Title to be announced”
15.30 – 15.50 Q&A: 15.50 – 16.00	Mark Cobbold Massachusetts General Hospital Cancer Center (USA) “Phosphorylated Neoantigens: targets for (anti-tumor) immunity in man” SESSION 3: Title to be confirmed Session Chair: to be confirmed
16.00 – 16.20 Q&A: 16.20 – 16.30	Federica Cavallo Molecular Biotechnology Center, University of Turin (Italy) “DNA vaccination against conserved TAA - a preclinical perspective”
16.30 – 16.50 Q&A: 16.50 – 17.00	Victor Klimyuk Icon Genetics GmbH, Halle/Saale (Germany) “Plant-based transient expression technology and cancer vaccines production”
17.00 – 17.20 Q&A: 17.20 – 17.30	Jane Lebkowski Asterias Biotherapeutics, Inc. Fremont (USA) “Development of a Telomerase- Based Allogeneic Dendritic Cell Therapeutic Vaccine for Lung Cancer: Translation to the Clinic”
17.30	WELCOME RECEPTION serving drinks and canapés <i>Bapsy Hall</i>
18.00 – 20.00	POSTER SESSION 1 including poster judging <i>Bapsy Hall</i>

Day 2 - Tuesday 13 September 2016

08.30 – 09.00

COFFEE *Bapsy Hall*

SESSION 4: Title to be confirmed

Session Chair: to be confirmed

09.00 – 09.20

Q&A: 09.20 – 09.30

Sergio Quezada UCL Institute, London (UK)

“Defining the immune and antigenic landscape of cancer”

09.30 – 09.40

Q&A: 09.40 – 09.45

Proffered Paper 2: **Author to be selected**

“Title to be announced”

09.45 – 10.05

Q&A: 10.05 – 10.15

Dario Neri Institute of Pharmaceutical Sciences (ETH) & Philochem AG, Zurich (Switzerland)

“Delivery of immunocytokines for local and distant immune control”

10.15 – 10.45

COFFEE BREAK *Bapsy Hall*

SESSION 5: Title to be confirmed

Session Chair: to be confirmed

10.45 – 11.05

Q&A: 11.05 – 11.15

Kate Cuschieri Specialist Virology Centre, Royal Infirmary of Edinburgh (UK)

Sarah Howie MRC Centre for Inflammation Research, University of Edinburgh (UK)

“HPV lifecycle and immunity - implications for human cancer and prophylactic vaccination”

11.15 – 11.35

Q&A: 11.35 – 11.45

Lena M. Kranz TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University (Germany)

“A systemic liposomal mRNA vaccine for cancer immunotherapy”

11.45 – 12.05

Q&A: 12.05 – 12.15

Emma King University of Southampton (UK)

“HNSCC as a model for immunotherapy”

12.15 – 12.45

Q&A: 12.45 – 13.00

Satellite Symposia

13.00 – 14.00

LUNCH *Bapsy Hall*

SESSION 6: Title to be confirmed

Session Chair: to be confirmed

14.00 – 14.20

Q&A: 14.20 – 14.30

Stephan Wagner Medical University of Vienna (Austria)

“B-cells in solid cancers - an emerging target for immunotherapy?”

14.30 – 14.40

Q&A: 14.40 – 14.45

Proffered Paper 3: **Author to be selected**

“Title to be announced”

14.45 – 15.05

Q&A: 15.05 – 15.15

Klaus Okkenhaug Babraham Institute, Cambridge (UK)

“PI3K δ as a target for cancer immunotherapy”

15.15 – 17.15

POSTER SESSION 2 including poster judging *Bapsy Hall*

SESSION 7: Title to be confirmed

Session Chair: to be confirmed

17.15 – 17.35

Q&A: 17.35 – 17.45

Sjoerd van der Burg Leiden University Medical Center, Leiden (Netherlands)

“The roles of chemotherapy in controlling adaptive immune responses in cancer”

17.45 – 18.05

Q&A: 18.05 – 18.15

Martijn den Brok NCMLS, Radboud University Nijmegen Medical Centre (Netherlands)

“Image-guided ablation as immunotherapy”

18.15 – 18.35
Q&A: 18.35 – 18.45

David Adams Institute of Immunology and Immunotherapy, University of Birmingham (UK)
“Immunotherapy for cancer in the liver - is it feasible and what are the hurdles”

19.30

CONFERENCE DINNER or free evening

Day 3 - Wednesday 14 September 2016

08.30 – 09.00

COFFEE *Bapsy Hall*

SESSION 8: Title to be confirmed
Session Chair: to be confirmed

09.30 – 09.50
Q&A: 09.50 – 10.00

Benoit van den Eynde Ludwig Institute for Cancer Research, Oxford (UK)
“What makes a good tumour antigen?”

10.00 – 10.20
Q&A: 10.20 – 10.30

Thomas J. Sayers Centre for Cancer Research, Maryland (USA)
“Can natural products enhance cancer cell death to improve immunotherapy?”

10.30 – 10.50
Q&A: 10.50 – 11.00

Vincenzo Cerundolo Weatherall Institute of Molecular Medicine, Oxford (UK)
“Ability of tumour micro-environment to hamper innate and adaptive immunity for cancer”

11.00 – 11.30

COFFEE BREAK *Bapsy Hall*

SESSION 9: Title to be confirmed
Session Chair: to be confirmed

11.30 – 12.00
Q&A: 12.00 – 12.15

Keynote Lecture
Pandurangan Vijayanand La Jolla Institute for Allergy and Immunology (USA)
“Transcriptome analysis of tumour infiltrating immune cells”

12.15 – 12.30

SUMMARY, PRESENTATION OF AWARDS CERTIFICATES
PHOTOGRAPHS & CLOSE OF THE MEETING

12.30

LUNCH & DEPART *Bapsy Hall*